Phase I Single Ascending Dose/Multiple Ascending Dose in Patients Treated With AZD7762 and Irinotecan

A Phase I Open-label, Multi-center, Dose-escalation and Safety Expansion Study to Assess Safety, Tolerability, and Pharmacokinectics of AZD7762 Administered as a Single Intravenous Agent and in Combination With Weekly Standard Dose of Irinotecan in Patients With Advanced Solid Malignancies.

This is an open-label, multi-center, dose-escalation and safety expansion, Phase I study to evaluate the safety, tolerability, and pharmacokinectics and to investigate biomarker changes of AZD7762 administered as a single intravenous unit and in combination with irinotecan. The study is sponsored by AstraZeneca.

Inclusion Criteria:

• Advanced solid tumors for which standard treatment doesn't exist or is no longer effective.
• Must be suitable for treatment with irinotecan
• Relatively good overall health other than your cancer

Exclusion Criteria:

• Poor bone marrow function (not producing enough blood cells)
• Serious heart conditions
• Poor liver or kidney function
• Any prior anthracycline treatment